CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

BioCryst Q3 revenue rises 13% on ORLADEYO sales

By Reuters News


Overview

  • U.S. rare disease drugmaker's Q3 revenue rose 13% yr/yr, driven by ORLADEYO sales and CareMed transition

  • Q3 net income increased significantly from a year earlier

  • Company maintained 2026 ORLADEYO revenue guidance, raised total revenue outlook for the year


Outlook

  • BioCryst maintains 2026 ORLADEYO revenue guidance of $625 mln to $645 mln

  • Company raises 2026 total revenue guidance to $715 mln-$730 mln

  • Company lowers 2026 non-GAAP operating expense guidance to $415 mln-$425 mln


Result Drivers

  • CAREMED TRANSITION - Co said Q3 revenue growth benefited from the transition to CareMed as its sole-source specialty pharmacy partner, which built initial inventory of ORLADEYO to support patient demand

  • ORLADEYO PELLET LAUNCH - Co said launch of ORLADEYO oral pellets in pediatric patients began in August, with early reimbursement strong and new prescriptions ahead of expectations


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 EPS

$0.14

Q3 Net Income

$37.92 mln

Q3 Operating Expenses

$126.96 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for BioCryst Pharmaceuticals, Inc. is $17.50, about 104.2% above its November 3 closing price of $8.57


Reuters Recommended Reads

  • Nov 2 - Syndax Pharmaceuticals Q3 revenue rises 82% on cancer drug sales

  • Nov 2 - Travere Q3 product sales nearly double on FILSPARI growth

  • Nov 3 - Mirum Pharmaceuticals Q3 net product sales surge, outlook raised


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.